Billionaire technology investor Peter Thiel has recently been investing big into Compass Pathways – a start-up company in the psychedelics space seeking to treat mental health disorders using psilocybin therapy. Psilocybin is an active ingredient in some species of mushrooms, often referred to as ‘magic mushrooms’. Compass Pathways has already raised $116.2 million and currently has an implied valuation of $800 million – close to unicorn status.
In the upcoming months, Compass Pathways is expected to go public in a major IPO, and we expect its valuation to exceed $1 billion.
Over the last two years, Psychstocks Founder Gerard Adams has become very well-educated about the emerging psychedelics industry. Recently in partnership with Inc.com, Gerard interviewed Dr. Rick Doblin, the world’s leading advocate for the medicinal use of psychedelics. Doblin is the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS) the largest non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics.
Doblin formed MAPS in 1986 to advocate for studying psychedelics as a potential treatment for emotional trauma. After 31 years of persistence and after raising $80 million from donors, the FDA in August 2017 granted Breakthrough Therapy Designation to MDMA-assisted psychotherapy for PTSD. Currently, MAPS is in Phase 3 clinical trials examining how MDMA can treat PTSD and Doblin believes the FDA is set to approve MDMA-assisted therapy for PTSD by 2022, with the treatment likely to become widely available during the following year.
Earlier this year, a lawmaker in New York State introduced a bill to decriminalize psilocybin mushrooms by removing the main active ingredient from the state’s list of controlled substances. In the upcoming months, the issue of legalization of psilocybin is going to become a major mainstream issue in the U.S. and many investors will be seeking ways to capitalize immediately on the rapidly emerging psychedelics industry.
After doing extensive research for months, Psychstocks Founder Gerard Adams has determined that there is one company that is already listed for trading today that is best positioned to capitalize on the rapidly emerging psychedelics space: Numinus Wellness (TSXV: NUMI).
Gerard recently spoke to Payton Nyquvest the CEO of NUMI who is a well-respected leader in the psychedelics space due to his focus on using psychedelic medicines to treat mental health issues. NUMI’s operations consist of Numinus Bioscience, a testing and research facility that can leverage the emerging market of psychedelic therapies to address mental illness, addictions and PTSD; Numinus Wellness, a treatment and healing centre model that the company aims to scale globally; and Numinus R&D, which is creating partnerships with leading research groups to advance practice and understanding in the space,
NUMI has a major first mover advantage over other public companies in this space. NUMI has been issued a dealer’s licence under the Controlled Substances Act in July 2019, allowing the company to play an important role in the areas of psychedelic substances research, testing and global distribution.
NUMI can test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline. NUMI is amending its licence to soon include activities such as R&D, import/export and packaging/labelling to become the leading psychedelics drugs marketing and distribution company.
NUMI closed yesterday at $0.27 per share and we strongly urge you to begin researching the company immediately.
Past performance is not an indicator of future returns. Psychstocks is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. The parent company of Psychstocks has been compensated by NUMI USD$30,000 cash for a marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.